Trial · NCT02697734
Adverse events425
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 425
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo Controlled Period - Osilodrostat Arm. | 2 | 48 | |
| other | Anaemia | Blood and lymphatic system disorders | Placebo Controlled Period - Placebo Arm. | 2 | 25 | |
| other | Anaemia | Blood and lymphatic system disorders | Overall Study Period - Osilodrostat Arm. | 2 | 48 | |
| other | Anaemia | Blood and lymphatic system disorders | Overall Study Period - Placebo Arm. | 1 | 25 | |
| other | Anaemia | Blood and lymphatic system disorders | Overall Study Period - All Participants. | 3 | 73 | |
| other | Palpitations | Cardiac disorders | Placebo Controlled Period - Osilodrostat Arm. | 0 | 48 | |
| other | Palpitations | Cardiac disorders | Placebo Controlled Period - Placebo Arm. | 2 | 25 | |
| other | Palpitations | Cardiac disorders | Overall Study Period - Osilodrostat Arm. | 2 | 48 | |
| other | Palpitations | Cardiac disorders | Overall Study Period - Placebo Arm. | 0 | 25 | |
| other | Palpitations | Cardiac disorders | Overall Study Period - All Participants. | 2 | 73 | |
| other | Tachycardia | Cardiac disorders | Placebo Controlled Period - Osilodrostat Arm. | 6 | 48 | |
| other | Tachycardia | Cardiac disorders | Placebo Controlled Period - Placebo Arm. | 0 | 25 | |
| other | Tachycardia | Cardiac disorders | Overall Study Period - Osilodrostat Arm. | 8 | 48 | |
| other | Tachycardia | Cardiac disorders | Overall Study Period - Placebo Arm. | 1 | 25 | |
| other | Tachycardia | Cardiac disorders | Overall Study Period - All Participants. | 9 | 73 | |
| other | Adrenal insufficiency | Endocrine disorders | Placebo Controlled Period - Osilodrostat Arm. | 7 | 48 | |
| other | Adrenal insufficiency | Endocrine disorders | Placebo Controlled Period - Placebo Arm. | 0 | 25 | |
| other | Adrenal insufficiency | Endocrine disorders | Overall Study Period - Osilodrostat Arm. | 12 | 48 | |
| other | Adrenal insufficiency | Endocrine disorders | Overall Study Period - Placebo Arm. | 6 | 25 | |
| other | Adrenal insufficiency | Endocrine disorders | Overall Study Period - All Participants. | 18 | 73 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02697734/events